Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 7/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | GCGR | P47871 | 9/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | GCG | P01275 | 4/20 | 0.39 |
| ▸ | GLP1R | P43220 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | GIPR | P48546 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2653230 | 1.00 | PPARD (0.46) | PPARDPPARAGCGRMCL1GCG | |
| SCHEMBL2659998 | 0.95 | PPARD (0.47) | PPARDPPARAGCGRMCL1GCG | |
| SCHEMBL2660000 | 0.95 | PPARD (0.47) | PPARDPPARAGCGRMCL1GCG | |
| SCHEMBL2653983 | 0.93 | GCGR (0.48) | PPARDPPARAGCGRMCL1GCG | |
| SCHEMBL2653984 | 0.93 | GCGR (0.48) | PPARDPPARAGCGRMCL1GCG | |
| SCHEMBL2659283 | 0.93 | PPARD (0.44) | PPARDPPARAGCGRMCL1GCG | |
| SCHEMBL2659285 | 0.93 | PPARD (0.44) | PPARDPPARAGCGRMCL1GCG | |
| SCHEMBL2653594 | 0.92 | GCGR (0.47) | PPARDPPARAGCGRMCL1GCG | |
| SCHEMBL2659504 | 0.92 | GCGR (0.47) | PPARDPPARAGCGRMCL1GCG | |
| SCHEMBL2653021 | 0.92 | PPARD (0.43) | PPARDPPARAGCGRMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| US-8084489-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2010-06-03 | — | — | US | disclosed |
| EP-1856090-B1 | SUBSTITUTED THIOPHENE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2009-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137417-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | PPARD 145/4885PPARA 211/4885GCGR 2/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | PPARD 178/4885PPARA 130/4885GCGR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.